Skip to Content

New Drug Approvals Archive - June 2003

June 2003

Uroxatral (alfuzosin) Extended-Release Tablets

Date of Approval: June 12, 2003
Company: Sanofi Synthelabo
Treatment for: Benign Prostatic Hyperplasia

Uroxatral (alfuzosin) an alpha-1-adrenergic receptor antagonist, is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

FluMist (Influenza Virus Vaccine, Live, Intranasal)

Date of Approval: June 17, 2003
Company: MedImmune Vaccines, Inc
Treatment for: Influenza Prophylaxis

FluMist is a live trivalent nasally administered vaccine intended for active immunization for the prevention of influenza.

Xolair (omalizumab) Subcutaneous Injection

Date of Approval: June 20, 2003
Company: Genentech, Inc.
Treatment for: Asthma -- Maintenance, Urticaria

Xolair (omalizumab) is a monoclonal antibody indicated for the treatment of patients with moderate to severe persistent asthma, and chronic idiopathic urticaria.

Reyataz (atazanavir sulfate) Capsules

Date of Approval: June 20, 2003
Company: Bristol Myers Squibb
Treatment for: HIV Infection

Reyataz is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Bexxar (Tositumomab and Iodine I 131 Tositumomab)

Date of Approval: June 27, 2003
Company: Corixa Corporation
Treatment for: non-Hodgkin's Lymphoma

Bexxar is a dual-action therapy that combines the tumor-targeting ability of a cytotoxic monoclonal antibody and the therapeutic potential of radiation. Bexxar is indicated for the treatment of Non-Hodgkin’s lymphoma.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.